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Abstract
The HIV-1 gp120-gp41 complex, which mediates viral fusion and cellular entry, undergoes rapid evolution within its external
glycan shield to enable escape from neutralizing antibody (NAb). Understanding how conserved protein determinants
retain functionality in the context of such evolution is important for their evaluation and exploitation as potential drug and/
or vaccine targets. In this study, we examined how the conserved gp120-gp41 association site, formed by the N- and C-
terminal segments of gp120 and the disulfide-bonded region (DSR) of gp41, adapts to glycan changes that are linked to
neutralization sensitivity. To this end, a DSR mutant virus (K601D) with defective gp120-association was sequentially
passaged in peripheral blood mononuclear cells to select suppressor mutations. We reasoned that the locations of
suppressors point to structural elements that are functionally linked to the gp120-gp41 association site. In culture 1, gp120
association and viral replication was restored by loss of the conserved glycan at Asn136 in V1 (T138N mutation) in
conjunction with the L494I substitution in C5 within the association site. In culture 2, replication was restored with deletion
of the N139INN sequence, which ablates the overlapping Asn141-Asn142-Ser-Ser potential N-linked glycosylation sequons in
V1, in conjunction with D601N in the DSR. The 136 and 142 glycan mutations appeared to exert their suppressive effects by
altering the dependence of gp120-gp41 interactions on the DSR residues, Leu593, Trp596 and Lys601. The 136 and/or 142
glycan mutations increased the sensitivity of HIV-1 pseudovirions to the glycan-dependent NAbs 2G12 and PG16, and also
pooled IgG obtained from HIV-1-infected individuals. Thus adjacent V1 glycans allosterically modulate the distal gp120-
gp41 association site. We propose that this represents a mechanism for functional adaptation of the gp120-gp41
association site to an evolving glycan shield in a setting of NAb selection.
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Introduction
The HIV-1 envelope glycoprotein (Env) complex comprises a
trimer of gp120 subunits in non-covalent association with a trimer
of transmembrane gp41 subunits and mediates viral attachment,
membrane fusion and viral entry (for review see [1,2]). Within
gp120, 5 conserved regions (C1–C5) alternate with 5 variable
regions (V1–V5). The conserved regions largely form the gp120
core comprised of inner and outer subdomains that are bridged by
4 antiparallel b-strands (the bridging sheet), whereas the variable
regions form external solvent-exposed loops [3,4,5,6,7,8]. gp120 is
anchored to the viral envelope by the trimeric transmembrane/
fusion glycoprotein, gp41. The ectodomain of gp41 comprises an
N-terminal fusion peptide linked through N- and C-terminal a-
helical heptad repeat sequences (HR1 and HR2, respectively) to a
C-terminal membrane anchor and cytoplasmic tail. A central
disulfide-bonded loop region or DSR joins HR1 to HR2 (Fig. 1A,
B).
The membrane fusion and viral entry function of gp120-gp41
involves conformational changes that are triggered by receptors. CD4
ligation is believed to reorganize V1V2 and V3 to expose a binding
site for the chemokine receptors CCR5 and CXCR4, which function
as fusion cofactors [3,4,5,6,9,10,11,12]. The V3 loop mediates
important contacts with the negatively charged N-terminal domain
and extracellular loop 2 of CCR5 and CXCR4 and determines the
chemokine receptor preference of HIV-1 isolates. In a virion context,
CD4 binding causes an ‘‘opening up’’ of the gp120 trimer due to
outward rotation and displacement of gp120 monomers [10,12].
gp120-receptor interactions cause gp41 to transition from a
dormant metastable structure into a fusion active state [1,2,13,14].
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Structural transitions in gp41 that are associated with fusion
function include the formation of a ‘‘prehairpin intermediate’’
structure wherein a triple-stranded coiled coil of HR1 segments
provides a binding surface for the HR2, while studies with
synthetic peptides and glycoprotein mutants indicate that the
fusion peptide inserts into the target membrane [15,16,17,18,19].
Antiparallel HR1-HR2 interactions form a 6-helix bundle which
apposes the N- and C-terminal membrane inserted ends of gp41,
and the associated viral and cellular membranes, leading to
merger and pore formation [20,21,22,23,24].
How conformational signals are transmitted between receptor-
bound gp120 and gp41 to trigger the refolding of gp41 into the
fusion-active state is being elucidated. A gp120-gp41 association
site formed by the terminal segments of C1 and C5 of gp120 and
the central DSR of gp41 [25,26,27,28] may play an important role
in this process as mutations in the DSR can inhibit CD4-triggered
gp41 prehairpin formation and the initial hemifusion event [29].
Furthermore, the introduction of Cys residues to C5 and to the
DSR generates an inactive disulfide-linked gp120-gp41 complex
that is converted to a fusion-competent form by reduction [30,31].
These findings implicate the C1–C5-DSR synapse in maintaining
gp120-gp41 in the prefusion state and in subsequent transmission
of fusion activation signals emanating from receptor-bound gp120.
The terminal C1 and C5 gp41-contact regions project ,35-A˚
from a 7-stranded b-sandwich at the base of the gp120 inner
domain [8]. This b-sandwich appears to also play an important
role in conformational signalling between gp120 and gp41 by
linking CD4-induced structural changes in 3 structural layers of
gp120 that emanate from the b-sandwich to the activation of gp41
[32].
Understanding how conserved functional determinants of the
HIV-1 glycoproteins tolerate or adapt to the rapid evolution of
other Env regions is important for their evaluation and exploita-
tion as potential drug and/or vaccine targets. For example,
resistance to a novel low molecular weight fusion inhibitor, PF-
68742, is conferred by mutations in the DSR implicating this gp41
region as an inhibitor target [33]. Neutralizing antibodies exert
strong evolutionary pressures on Env that can result in an increase
in the number and/or a change in the position of potential N-
linked glycosylation sites (PNGSs) that modify NAb-Env interac-
tions [34,35]. V1V2 is a key regulator of neutralization resistance,
which generally correlates with its elongation and acquisition of
PNGSs [34,36,37,38,39,40,41,42,43,44]. Previously, we identified
the C1–C5-DSR association site as a conserved determinant that
exhibits structural and functional plasticity. This idea is based on
the finding that whereas the gp120-gp41 association function and
sequence of the DSR is conserved, the contribution of individual
DSR residues to gp120 anchoring and membrane fusion function
varies among HIV-1 strains and is controlled by V1V2 and V3
[28]. We proposed that this plasticity enables the maintenance of a
functional glycoprotein complex in a setting of host selective
pressures such as NAbs that drive the rapid coevolution of gp120
and gp41.
In the present study, we reveal a structural mechanism whereby
the conserved gp120-gp41 association site adapts to changes in the
glycan shield. Forced viral evolution was used to examine how the
gp120-gp41 complex adapts to overcome a mutation (K601D in
the DSR) that causes defective gp120-gp41 association. The
defective phenotype was restored by second site mutations leading
to the loss of PNGSs at V1 positions 136 and 142, the former
operating in conjunction with L494I in C5 of gp120 and the latter
requiring D601N in the DSR. The PNGS mutations appeared to
exert their suppressive effects by altering the dependence of gp120-
gp41 interactions on Leu593, Trp596 and Lys601 within the DSR.
The PNGS mutations were also linked to an increase in the
sensitivity of HIV-1 pseudovirions to neutralization by the glycan-
directed NAbs 2G12 and PG16. Our data implicate V1 glycans
linked to neutralization susceptibility in the allosteric modulation
of the gp120-gp41 association site. We propose that this represents
a mechanism for maintaining gp120-gp41 function in a setting of
NAb-driven Env evolution.
Results
Phenotype and long-term culture of the HIV-1AD8-K601D
DSR mutant
In this study, we subjected the gp120-gp41 association defective
DSR mutant HIV-1AD8-K601D to serial PBMC passage in order
to select suppressor mutations. We reasoned that the locations of
suppressors would point to structural elements that are function-
ally linked to the DSR, thereby shedding light on its role in Env
function. We first confirmed that the K601D mutation promoted
the shedding of gp120 into the culture supernatant of 293T cells
transfected with pcDNA3.1-AD8env, as determined by radioim-
munoprecipitation (Fig. 1C). Consistent with this finding,
K601D-mutated HIV-1AD8 virus particles were largely devoid of
gp120 (Fig. 1D). We note the presence of gp160 in the pelleted
virion preparations. It likely represents one of a number of non-
native Env forms that have been observed in virions and have
been implicated as immune decoys [45,46,47,48,49,50]. The
gp120 shedding defect did not appear to be associated with a
precursor processing defect as Western blotting with the gp41-
directed C8 monoclonal antibody (mAb), indicated that similar
amounts of gp41 were derived from gp160 for both WT and
K601D (Fig. 1E). Cell-to-cell fusion function was blocked by
K601D at sub-saturating Env conditions (Fig. 1F), while HIV-
1AD8 viral replication over 10 days in phytohemagglutinin-
stimulated peripheral blood mononuclear cells (PBMCs) from
independent donors was severely attenuated by the mutation
(Fig. 1G). The restoration of HIV-1AD8-K601D replication
competence was observed with sequential passage of cell-free
virus in independent PHA-stimulated PBMC cultures (Fig. 1G,
cultures P0 and P2).
Author Summary
The envelope glycoprotein gp120-gp41 complex of HIV-1
mediates receptor attachment and virus-cell membrane
fusion, leading to cellular entry. A shield of asparagine-
linked oligosaccharides occludes the gp120-gp41 protein
surface and evolution of this glycan shield provides a
means for evading circulating neutralizing antibody. Here
we examined how conserved structural elements of the
glycoprotein complex, in particular the gp120-gp41
association site, retain functionality in the context of
glycan shield evolution. This information is important for
the evaluation and exploitation of such conserved func-
tional determinants as potential drug and/or vaccine
targets. Our data indicate that the loss of either of 2
adjacent glycans in variable region 1 of gp120 leads to
changes in local and remote glycan-dependent epitopes
and that this is linked to a remodelling of gp120-gp41
interactions in order to maintain a functional gp120-gp41
complex. We propose that this represents a mechanism for
the functional adaptation of the gp120-gp41 association
site to an evolving glycan shield in a setting of neutralizing
antibody selection.
V1 Glycans Modulate HIV-1 gp120-gp41 Association
PLOS Pathogens | www.plospathogens.org 2 April 2013 | Volume 9 | Issue 4 | e1003218
Figure 1. Location and phenotype of K601D. A, Linear map of gp41. fp: fusion peptide, HR1: helical region 1, DSR: disulfide bonded region, HR2:
helical region 2, TMD: transmembrane domain, CT: cytoplasmic tail. Residue numbering is in accordance with HXB2 Env. Magenta circles denote the
residues mutated in this study. B, Alignment of the AD8 DSR amino acid sequence with consensus (CONS) sequences derived from HIV-1 main-group
subtypes and circulating recombinant forms (http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html). The residue numbers of amino acids
implicated in gp120 association [27,76] are indicated. C, gp120-gp41 association. Lysates of metabolically labelled WT, K601D or empty vector (mock)
transfected 293T cells (c) and corresponding culture supernatants (s) were immunoprecipitated with IgG14 and protein G Sepharose. Proteins were
analysed under reducing conditions in SDS-PAGE and scanned in a Fuji phosphorimager. Panel prepared from a single gel using Adobe Photoshop.
D, Virion characterization. HIV-1 virions produced by transfected 293T cells were pelleted from the culture supernatant through a 25% sucrose
cushion and analysed by reducing SDS-PAGE and Western blotting with DV-012 (anti-gp120) and mAb 183 (anti-CA). K601D.1 and K601D.2 are 2
independent clones of pAD8-K601D; NL4.3: virus derived from the pNL4.3 clone [116]. E, Lysates of 293T cells transfected with 1 or 0.25 mg pcDNA3.1-
AD8env vectors analysed by Western blot using the gp41-specific mAb, C8. The asterisk denotes degradation products of gp160. F, Cell-cell fusion.
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Genotypes of HIV-1AD8-K601D revertants
In order to identify suppressors of K601D, the env region was
PCR-amplified from genomic DNA isolated from infected cells at
days 20, 30, 40 and 50 for culture P0, and days 30 and 50 for
culture P2. The PCR products were cloned into the pDKAD8env
expression vector for DNA sequencing. The K601D mutation was
retained in P0 clones isolated at days 20 and 30 (FIG. 2A), when
replication was not observed in the mutant virus culture (FIG. 1G,
P0). The emergence of replication-competent virus at day 40 in
the P0 culture correlated with the appearance of L494I in C5 of
gp120 (6/6 clones), together with either a D601N pseudoreversion
(3/6 clones), and/or T138N, which abolishes a conserved PNGS
at position 136 (N136VT) within V1 of gp120 (3/6 clones). By day
50, when mutant viral replication approached that of WT, the
T138N/L494I/K601N triple mutation was present in 42% of
clones. A single clone (P0.D50.10) contained S144N, which ablates
the nearby PNGS at N142SS.
In an independent PBMC long-term culture (P2), the replication
competence of the mutant virus approached that of WT by the 3rd
passage (Fig. 1G, P2). Deletion of residues N139INN (DN139INN)
from V1, that results in the loss of overlapping PNGSs at positions
141 and 142 (N141N142SS), was observed in 3/14 P2 day-30
clones, while 2/14 possessed mutations at Thr138; K601N was also
observed in 50% of P2-day 30 clones (Fig. 2B). The dominant
genotypes in P2 day-50 clones were DN139INN together with
K601N, and K601N alone. A 2-residue N142S143 deletion was
observed in 1 day-50 clone (P2.D50.141), which also ablates the
overlapping PNGSs at 141 and 142. Interestingly, the L494I
mutation was not observed in P2 clones. These data indicate that
PNGSs in V1 are functionally linked to the gp120-gp41
association synapse.
Functional linkages between the DSR, PNGSs in V1, and
Leu494 in C5
To determine how replication was restored to the K601D virus
in the long-term PBMC cultures, we reconstructed the dominant
P0 and P2 genotypes in the context of the pAD8 proviral clone
and examined viral replication in two independent PBMC donors.
The P0 mutations, L494I within C5 and K601N within the DSR,
partially restored replication in the PBMCs of one donor but not
in the second, apparently less permissive donor (Fig. 3A and B;
P0 panels; Table S1). The T138N/L494I/K601D and
T138N/L494I/K601N genotypes exhibited near-WT replication
kinetics in PBMCs from both donors. These data suggest that
T138N, which ablates the PNGS at Asn136 within V1, and L494I
act synergistically to suppress K601D (and K601N). The analysis
of P2 genotypes in PBMC cultures indicated that the N139INN
deletion in V1 was not sufficient to suppress K601D, but its
combination with K601N led to near-WT levels of viral
replication (Fig. 3A, B; P2 panels).
The pDKAD8env expression vector was next employed to
further dissect the functional linkages between position 601 within
the DSR, the Asn136 and Asn141/142 PNGS mutations in V1 and
the L494I mutation in C5 in gp120-gp41 association and cell-cell
fusion assays. The results presented in Fig. 3C indicate that
K601D and K601N DSR mutations promote shedding of gp120
into culture supernatants of transfected cells by ,6.8- and 4.4-fold
with respect to WT, respectively, while cell-cell fusion activity was
reduced by ,85–90% (Fig. 3D; Table S1). These data indicate
that the K601D and K601N DSR mutations inhibit cell-cell fusion
function by destabilizing the gp120-gp41 complex. However, the
effect of K601N on Env function in the context of virus replication
appears to be donor dependent (see Fig. 3A and B). It may be
that lower receptor numbers and/or alternate coreceptor post-
translational modifications on target cells, or differences in target
cell population numbers [51,52,53,54] in the case of the latter
donor’s PBMCs do not enable the fusion-activation threshold to be
reached for K601N Env. A general correlation between the
restoration of cell-cell fusion activity and gp120-gp41 association
was observed for the P0 combination mutants. Thus L494I/
K601D exhibited ,50% of WT cell-cell fusion activity with
improved gp120-gp41 association, whereas T138N/L494I/
K601D and T138N/L494I/K601N were functionally similar to
the WT. The phenotype of T138N/K601D was an outlier as
gp120-gp41 association was improved by ,2-fold with respect to
K601D without a restorative effect on Env fusion function. These
data indicate that T138N and L494I act cooperatively to restore
gp120-gp41 association to K601D with concomitant restoration of
membrane fusion function and viral replication competence.
T138N-containing gp120 molecules migrated to lower molecular
weight positions with respect to WT in reducing SDS-PAGE,
consistent with loss of the glycan at Asn136 (Fig. 3C).
The DN139INN/K601D and DN139INN/K601N P2 clones
exhibited 74–77% of WT fusion activity (P,0.05) with only partial
restoration of gp120-gp41 association, even though only the latter
clone was competent for replication in PBMCs (Figs. 3A–D,
Table S1). The suppression of the K601N fusion and replication
phenotype by DN139INN is therefore not dependent on the full
restoration of gp120-gp41 association or on the L494I C5
mutation. gp120 molecules with the DN139INN mutation migrated
faster in SDS-PAGE than non-DN139INN-containing Envs, again
consistent with the loss of glycan (Fig. 3C). The DN139INN
mutation disrupts the overlapping N-linked glycosylation sequons:
Asn141-Asn142-Ser-Ser. Such overlapping N-linked glycosylation
sequons are observed in V1 of a subset of HIV-1 strains (http://
www.hiv.lanl.gov/content/sequence/NEWALIGN/align.
html#comp), although the position varies. Combining S144N (a
PNGS mutation observed in clone P0.D50.10) with K601N
resulted in almost identical fusion activity to DN139INN/K601N
(Fig. 3D), suggesting that loss of the Asn142 glycan can substitute
for the N139INN deletion.
Scanlan and coworkers [55,56] reported that gp120 derived
from virions produced in 293T cells and PBMCs is composed of
oligomannose type glycans, whereas monomeric gp120 produced
in 293T cells contains predominantly complex type glycans in
addition to the oligomannose type. It was therefore important to
determine whether the presence of complex type glycans on cell-
surface expressed Env was influencing the results of the cell-cell
fusion and gp120-gp41 association assays. Kifunensine, an a-
mannosidase I inhibitor that blocks the synthesis of Man5GlcNac2,
the precursor of hybrid and complex-type glycans [57], was used
to restrict Env glycosylation to the oligomannose type. The
293T effector cells were cotransfected with 1 mg pCAG-T7 plus 1 mg or 0.25 mg of pcDNA3.1-AD8env and then cocultured (16 h, 37uC) with BHK21
target cells that had been cotransfected with pc.CCR5 and pT4luc. The mean relative light units (RLU) 6 standard deviation of a representative
experiment is shown. G, Long-term PBMC culture of HIV-1AD8-WT and HIV-1AD8-K601D. Viruses produced by pAD8-transfected 293T cells were
normalized according to RT activity and then used to infect independent cultures of PHA stimulated PBMCs (cultures P0 and P2). The PBMCs used in
each passage were obtained from different donors. Cell-free virus collected at day 10 of each passage was normalized for RT activity and used to
infect fresh PHA stimulated PBMCs. The mean RT activity 6 standard deviation of duplicate samples obtained from culture supernatants is shown.
doi:10.1371/journal.ppat.1003218.g001
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culturing of Env-expressing 293T cells in increasing concentra-
tions of kifunensine did not appear to affect the efficiency of gp160
processing to gp120 and gp41, however, the resultant gp120
migrated faster than its counterpart expressed in the absence of
kifunensine. Furthermore, the gp120 and gp41 bands had a more
focused appearance relative to the corresponding glycoproteins
expressed under control conditions (Fig. S1A). These data are
consistent with homogeneous oligomannose type Env glycosyla-
tion due to the action of kifunensine [58]. We next examined the
effects of 10 mM kifunensine on the cell-cell fusion activities of the
T138N/L494I/K601N and DN139INN/K601N revertant Envs.
Figure S1B shows that the presence of kifunensine leads to a
Figure 2. Genotypes of HIV-1AD8-K601D revertants. The env region of proviral DNA isolated at days 20, 30, 40 and 50 from P0 (A), and days 30
and 50 from P2 (B) was amplified by PCR and cloned into pGEM-T or pDKAD8env. The entire env region present in individual clones was sequenced
using Bigdye terminator 3.1. The amino acid numbering is based on HXB2 Env.
doi:10.1371/journal.ppat.1003218.g002
Figure 3. Analysis of revertants. A and B, 14-day replication kinetics of representative P0 and P2 genotypes in PBMCs. Virus stocks produced in
293T cells were normalized according to RT activity and used to infect PHA stimulated PBMCs from 2 independent donors (A and B, respectively).
RT activity was measured in culture supernatants obtained at days 3, 7, 10 and 14 postinfection. The mean RT activity 6 standard deviation of
duplicate samples is shown. C, gp120-gp41 association. Lysates of metabolically labelled Env-expressing cells (c) and corresponding culture
supernatants (s) were immunoprecipitated with IgG14 plus protein G-Sepharose and subjected to reducing SDS-PAGE and phosphorimager
scanning. The panel was prepared from 2 gels obtained from a single experiment (representative of 3 independent experiments) using Adobe
Photoshop. gp120-shedding index was calculated according to the formula: ([mutant gp120]supernatant6[WT gp120]cell)/([mutant gp120]cell6[WT
gp120]supernatant) [26]. The data shown are the mean shedding indices 6 standard error from at least 3 independent experiments. D, Cell-cell fusion
activities of representative P0 and P2 genotypes. Assays were conducted with 0.25 mg AD8 Env expression plasmids as for FIG. 1F. Mean RLU 6
standard error is shown (n.3). ***, P,0.001 versus K601D, 2-tailed unpaired t test assuming unequal variances. E, T138N and DN139INN mutations on
a WT Env background do not affect cell-cell fusion activity (Mean RLU 6 standard error, n.3). F, T138N and DN139INN mutations on a WT Env
background do not affect the ability of Env-pseudotyped luciferase reporter viruses to mediate a single cycle of infection in U87.CD4.CCR5 cells. Mean
RLU 6 standard deviation from a representative experiment is shown.
doi:10.1371/journal.ppat.1003218.g003
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general elevation in the fusion activities of the 4 constructs tested.
Importantly, the presence of kifunensine did not affect the relative
fusion activities of the T138N/L494I/K601N and DN139INN/
K601N revertant Envs with respect to wild type and K601D.
These data were reflected in the gp120-gp41 association assay
where the shedding phenotype of K601D was restored to wild type
and near-wild type levels, respectively, in T138N/L494I/K601N
and DN139INN/K601N, in both the presence and absence of
kifunensine (Fig. S1C). Overall, these data indicate that the fusion
and gp120-gp41 association phenotypes of the cell-expressed
revertant Envs are not influenced by the presence of complex or
hybrid-type glycans.
We next asked whether the V1 PNGS mutations restored
function via a functional link to Asp or Asn at position 601 in the
DSR or whether a generalized enhancement in Env function
could explain the restored phenotypes. Figures 3E and F
indicate that T138N and DN139INN do not increase the cell-cell
fusion activity of surface expressed Env or the infectivity of Env-
pseudotyped luciferase reporter virus when introduced to the WT
background. We also noted that the L494I mutation in a WT
background did not substantially increase cell-cell fusion or gp120-
gp41 association (data not shown). These data are consistent with
specific functional crosstalk between the V1 glycans, the Asp601 or
Asn601 in the DSR and position 494 in C5.
Finally, we asked if the V1 PNGS mutations at 136 and 142
restored function via a specific link to position 601 in the DSR, or
whether deletion of any of the 6 PNGSs in V1V2 of the AD8
strain (Fig. 4A) could restore functional defects related to a DSR
mutation. To this end, we introduced T138N, S143N, S144N,
S158N, N160Q and S188N mutations to the WT and K601N
pDKADenv vectors and determined their effects on cell-cell fusion,
glycoprotein processing and gp120-gp41 association. Figure 4B
indicates that in a WT Env context, T138N and S188N did not
affect cell-cell fusion, S143N, S144N and N160Q led to small but
significant functional enhancements, whereas S158N blocked
fusion completely. Even though, most of the V1V2 glycan mutants
were fusogenic on a WT background, only T138N and S144N
restored function to K601N. A Western blot of DKADenv-
transfected 293T cell lysates with the gp41-specific mAb, C8,
confirmed that the mutant glycoproteins were expressed and
processed to gp41 at levels that were close to the WT (Fig. 4C).
Pulse-chase biosynthetic labeling followed by radioimmunopre-
cipitation with pooled IgG derived from HIV-1-infected individ-
uals (HIVIG) indicated WT-like gp120-gp41 association for
T138N, S143N, S144N, N160Q and S188N and a shedding
phenotype for the fusion-defective S158N (Fig. 4D). Near-WT
levels of gp120-gp41 association were observed for the fusion-
competent T138N/K601N mutant, whereas S144N/K601N,
which is also fusion competent, exhibited a mild gp120 shedding
phenotype. By contrast, improvements in gp120-gp41 association
did not follow the combination of K601N with S143N, S158N,
N160Q or S188N, consistent with their lack of fusion activity.
Overall, these data are consistent with a specific functional linkage
between the DSR and the Asn136 and Asn142 glycosylation sites in
V1.
Mechanism of reversion
The effects of reversion-associated mutations on gp120-CD4
binding, sensitivity of cell-cell fusion and infectivity to sCD4
inhibition, CCR5 utilization and sensitivity to the HR2-based
fusion inhibitor peptide, C34, were next examined in order to
further elucidate the mechanism whereby function was restored in
the context of a mutated DSR. CD4 binding curves were
generated by incubating a constant amount of biosynthetically
labelled WT and mutated monomeric gp120 with serial dilutions
of sCD4, coimmunoprecipitation of gp120-sCD4 complexes with
mAb OKT4, followed by SDS-PAGE and densitometry of gp120
bands. Similar CD4 binding curves were observed for WT,
T138N/L494I and DN139INN gp120 mutants (Fig. 5A). The
sCD4 EC50 for WT, T138N/L494I and DN
139INN gp120 was
,0.5 nM, which approximates the published affinity range of
sCD4 for monomeric gp120 [59]. These data indicate that the
glycosylation site mutations in V1 and L494I in C5 did not alter
the CD4-binding ability of monomeric gp120. We next compared
the sensitivity of T138N/L494I/K601N-, DN139INN/K601N-
and WT-Env-mediated fusion to inhibition with sCD4. The Env-
expressing 293T cells were incubated with a sCD4 dilution series
for 3.5 h prior to an 8-h coculture with CD4-plus-CCR5-
expressing BHK21 targets harboring a luciferase reporter.
Figure 5B indicates that WT and T138N/L494I/K601N have
almost identical sensitivities to sCD4 with IC50s of ,60 mg/ml,
which are comparable to previously published values for both T
cell-line adapted and primary HIV-1 Envs [60]. The DN139INN/
K601N inhibition curve, however, was shifted by ,1log2 to the
left, indicating that this Env is slightly more resistant to sCD4, even
though monomeric gp120 containing the DN139INN mutation had
similar sCD4 binding characteristics to WT and T138N/L494I.
We sought to recapitulate the cell-cell fusion data in a virus
infection system. For this, we used TZM-bl luciferase reporter cells
and the CD4-IgG2 fusion protein wherein the Fv regions of IgG
have been replaced by domains 1 and 2 of CD4. The tetrameric
nature of CD4-IgG2 leads to a reduction in IC50 relative to
monomeric sCD4 [60]. Complete inhibition of virus infectivity
was achieved with 15 mg/ml of CD4-IgG2 with WT and T138N/
L494I/K601N exhibiting similar sensitivities to the fusion protein
(IC50,0.3 mg/ml) (Fig. 5C). As was observed in the cell-cell
fusion assay, the DN139INN/K601N virus inhibition curve was
shifted to the left, with an IC50 of ,1.3 mg/ml, confirming that
DN139INN/K601N is more resistant to the CD4-based inhibitor
relative to WT and T138N/L494I/K601N in a virion context.
The abilities of T138N/L494I/K601N, DN139INN/K601N
and WT Envs to utilize a panel of CCR5 coreceptor mutants were
next compared in order to determine if alterations to the mode of
CCR5 engagement could account for reversion. The results
presented in Fig. 5D indicate that the T138N/L494I/K601N,
DN139INN/K601N and WT Envs exhibited almost identical
patterns of mutant CCR5 utilization. For example, Q4A and
Y14A (N-terminal domain, Nt), H88A (extracellular loop 1,
ECL1), K171A, E172A and Q188A (extracellular loop 2, ECL2),
and F264A and R274A (extracellular loop 3, ECL3) CCR5
mutants supported fusion with the 3 Env constructs to the same
extent as WT CCR5, whereas fusion with Q280A (extracellular
loop 3) was decreased to 25–40% of WT CCR5 activity. We also
compared the abilities of T138N/L494I/K601N, DN139INN/
K601N and WT Envs to mediate cell-cell fusion with the CCR5-
Y14N tyrosine sulfation mutant, which exhibits a lower affinity for
gp120-gp41 and functions as a HIV-1 coreceptor in a cell surface
concentration-dependent manner [61]. The coreceptor activity of
WT CCR5 for WT and T138N/L494I/K601N remained at
consistently high levels for fusion with BHK21 targets cotrans-
fected with a constant amount of pT4luc vector and a dilution
series of pc.CCR5 DNA; the fusion activity of DN139INN/K601N
was slightly diminished across the pc.CCR5 dilution series
(Fig. 5E), consistent with the data presented in Fig. 3D. These
data are consistent with previous findings indicating that trace
amounts of CCR5 are sufficient to mediate efficient fusion and
entry by HIV-1 [61]. By contrast, fusion mediated by the 3 Env
constructs exhibited a strict dependence on the amount of
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Figure 4. Evidence for a specific functional linkage between position 601 of the DSR and the Asn136 and Asn142 glycans of V1. A,
Alignment of V1V2 and corresponding DSR sequences. PNGSs are highlighted in green and numbered according to HXB2 Env. Variable residues in
the DSR are highlighted in grey. CONS, subtype consensus sequence. B, Cell-cell fusion. Assays were conducted with 0.25 mg Env expression plasmids
as for FIG. 1F. Mean RLU 6 standard error (n$4) is shown. |, P,0.05; |, P,0.01 versus WT; *, P,0.05; ** P,0.01 versus K601N; 2-tailed unpaired t test
assuming unequal variances. C, Lysates of Env-expressing 293T cells were analysed by Western blot using the gp41-specific mAb, C8. The asterisk
denotes degradation products of gp160. D, gp120-gp41 association. Lysates of metabolically labelled Env-expressing cells (c) and corresponding
culture supernatants (s) were immunoprecipitated with HIVIG plus protein G-Sepharose and subjected to reducing SDS-PAGE and phosphorimager
scanning. The data are representative of 2 independent experiments. gp120-shedding indices (mean 6 standard error) are shown below the
corresponding immunoprecipitations and were calculated as for FIG. 3C from 2 independent experiments.
doi:10.1371/journal.ppat.1003218.g004
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transfected CCR5-Y14N plasmid without any significant changes
in the CCR5-Y14N concentration curves due to the Env
mutations being observed. These data indicate that the restoration
of function to the mutated DSR by the T138N/L494I or
DN139INN suppressor mutations in gp120 is unlikely to be a
result of altered CD4 and CCR5 utilization.
We considered that an increase in the efficiency of a post
receptor-binding event, such as 6-helix bundle formation, could
aid in the functional compensation of the DSR mutations. We
therefore asked if the mutations in gp120 and K601N led to
changes in sensitivity to the HR2 synthetic peptide analogue, C34,
which blocks fusion by binding to the coiled coil of HR1 helices in
a receptor-triggered prehairpin intermediate conformation of gp41
[17,62]. We expect that faster 6-helix bundle folding kinetics
would correspond to decreased C34 sensitivity. Figure 5F
indicates that T138N/L494I/K601N, DN139INN/K601N and
WT Envs exhibited almost identical C34 fusion inhibition curves
with IC50s of ,100 nM. These data indicate that the T138N/
L494I/K601N reversion mechanism is unlikely to be due to
changes in gp120-receptor interactions nor post-receptor binding
events such as efficiency of 6-helix bundle formation, whereas
DN139INN/K601N may be subtly altered in sCD4-induced
changes that inhibit membrane fusion function.
Modulation of the gp120-gp41 association site by
adjacent glycosylation sites in V1
The DSR mediates association with gp120 and may play a role
in the activation of gp41 by responding to receptor-induced
changes in gp120 [27,28,29,30,31]. To better understand how
glycosylation in V1 impacts on gp120-gp41 interactions, we
assessed the functional effects of T138N, L494I, T138N/L494I
and DN139INN mutations on two other gp120 contact residues
within the DSR, Leu593 and Trp596, in addition to Lys601 [27,28].
While L593V and K601D mutations resulted in decreased gp120-
gp41 association and cell-cell fusion function, the W596L mutant
exhibited WT levels of gp120-gp41 association but reduced cell-
cell fusion by,40% at subsaturating Env (P,0.02, 2 sample t-test,
unequal variances) (Fig. 6A, B). Figures 6A and B indicate that
T138N had no effect on cell-cell fusion when combined with
L593V or K601D, whereas small improvements in glycoprotein
association and fusion function were observed when L494I was
added to the DSR mutants; wild type levels of gp120-gp41
association and fusion were attained when both T138N and L494I
were combined with L593V or K601D. By contrast, W596L
exhibited WT fusion levels in combination with T138N. The
N139INN deletion did not provide any improvement to L593V
fusogenicity, but restored increasing levels of fusion function to
K601D and W596L, respectively. These data indicate that T138N
in V1 alters the gp120-gp41 association site such that fusion
function is less dependent on Trp596 and, when L494I is also
present, on Leu593 and Lys601. The N139INN deletion renders
fusion function less dependent on Trp596 and Lys601.
Modulation of neutralization sensitivity by adjacent
glycans in V1
Previous studies have shown that larger numbers of potential N-
linked glycans in V1V2 correlate with resistance to NAb
[34,37,38,39,40,42]. We therefore asked whether the T138N
and DN139INN mutations were linked to changes in the
neutralization sensitivity of Env-pseudotyped reporter viruses.
The results (Fig. 7) show step-wise ,0.5log10-increases in the
neutralization sensitivities of T138N and DN139INN to the
monoclonal NAb 2G12, which is directed to a glycan cluster
involving Asn295, Asn332 Asn339, Asn386 and Asn392 on the outer
face of gp120 [63,64,65,66,67,68]). The 2G12 IC50s for WT,
T138N and DN139INN were 13, 4 and 1.5 mg/ml, respectively. In
the case of PG16, which recognizes an epitope in V1V2 involving
the Asn156 and Asn160 oligomannose glycans [7,69,70], neutral-
ization was enhanced for DN139INN only (IC50 = 0.075 and 0.015;
IC90 = 1.6 and 0.16 mg/ml, respectively, for WT and DN
139INN).
By contrast, neutralization by IgGb12 (CD4 binding site [71,72])
and 2F5 (membrane proximal external region of gp41 [73,74,75])
was not affected by the V1 mutations. Pooled IgG from HIV-1
infected individuals (HIVIG) was used as a reference reagent. In
this case, a reproducible ,2-fold increase in sensitivity to
neutralization by HIVIG was observed with the V1 PNGS
mutations (IC50,550 mg/ml for WT, 280 mg/ml for T138N and
DN139INN) indicating that these glycans are likely to modulate
neutralization epitopes recognized by human immune sera. These
data indicate that the adjacent V1 glycans shown here to modulate
the gp120-gp41 association site are linked to neutralization
resistance.
Figure 5. Receptor binding properties and C34 susceptibility of revertants. A, CD4 binding by WT and mutated gp120 molecules. Soluble
CD4 binding curves were obtained by incubating a constant amount of biosynthetically labelled WT and mutated gp120 with the indicated amounts
of sCD4. gp120-sCD4 complexes were coimmunoprecipitated with mAb OKT4 and protein G-Sepharose, followed by reducing SDS-PAGE and
densitometry of gp120 bands. gp120-sCD4 binding is expressed as a percentage of gp120 immunoprecipitated by IgG14. The mean 6 standard
deviation from 2 independent experiments is shown. B, Inhibition of cell-cell fusion by sCD4. Assays were conducted with 0.25 mg Env expression
plasmids as for Fig. 1F except that Env-293T cells were incubated with a dilution series of sCD4 for 3.5 h prior to coculture with CD4-plus-CCR5-
expressing BHK21 targets for 8 h. The data are expressed as a percentage of the maximal fusion achieved by each Env and represent the means 6
standard error from 4 independent experiments. WT: blue square; T138N/L494I/K601N: red triangle; DN139INN/K601N: green ‘‘X’’. C, Inhibition of
infection by sCD4-IgG2. WT, T138N/L494I/K601N and DN139INN/K601N viruses were incubated with sCD4-IgG2 for 4 h at 37uC and then added to
TZM-bl cells. The cells were lysed 48 h after infection and the luciferase activity present in the lysates determined. The data are expressed as a
percentage of the maximal infection achieved by each virus and represent the means 6 standard deviation from a single experiment performed in
triplicate. Symbols are as for Fig. 5B. D, Utilization of CCR5 mutants in cell-cell fusion by T138N/L494I/K601N and DN139INN/K601N. Assays were
conducted with 0.25 mg Env expression plasmids as for Fig. 1F. The fusion activity of each Env clone was normalized against its fusion activity with
WT CCR5. Mean relative fusion activity 6 standard deviation is shown from a representative experiment. CCR5 N-terminal domain: Nt, extracellular
loops 1, 2, and 3: ECL1, ECL2 and ECL3, respectively. E, Utilization of the CCR5-Y14N coreceptor mutant in cell-cell fusion by T138N/L494I/K601N and
DN139INN/K601N. 293T effector cells cotransfected with 1 mg pCAG-T7 plus 0.25 mg Env expression plasmids were cocultured (16 h, 37uC) with BHK21
targets cotransfected with 1 mg pT4luc plus the indicated amounts of WT or Y14N-mutated pc.CCR5 prior to luciferase assay. The fusion activity of
each Env clone was normalized against its fusion activity with WT CCR5. Mean relative fusion activity 6 standard deviation is shown from a
representative experiment. F, Sensitivity of T138N/L494I/K601N and DN139INN/K601N to the fusion inhibitor peptide, C34. 293T effector cells
cotransfected with 1 mg pCAG-T7 plus 0.25 mg Env expression plasmids were cocultured (16 h, 37uC) with BHK21 targets cotransfected with pT4luc
plus pc.CCR5 in the presence of the indicated amounts of C34 prior to luciferase assay. The data are expressed as a percentage of cell-cell fusion
activity in the absence of inhibitor (mean 6 standard error; n = 3).
doi:10.1371/journal.ppat.1003218.g005
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Discussion
The gp120-gp41 complex of HIV-1 is maintained through
interactions between C1 and C5 of gp120 with the DSR of gp41.
Receptor engagement elicits a conformational signal that is
transmitted through gp120 and sensed by the gp120-contact
residues to activate the membrane fusion potential of gp41. In this
study, we forced the evolution of a DSR mutant (K601D) with
defective gp120-gp41 association, reasoning that the locations of
emergent 2nd site mutations that suppress the defect will point to
structural elements within gp120-gp41 with functional links to the
DSR. The loss of glycans at Asn136 or Asn142 within V1, the
former acting in conjunction with L494I in C5 and the latter with
a D601N pseudoreversion, largely suppressed the functional
defects, with Env function becoming less dependent on particular
gp120-contact residues (Leu593, Trp596 and Lys601) within the
DSR.
One mechanism of reversion involved the acquisition of L494I
in C5 that led to slightly improved gp120-gp41 association and
fusion function with Asp601, but a WT-like phenotype also
required deletion of the glycan at Asn136 in V1 through T138N.
Outgrowth by Asn601-containing clones suggested that the
negative charge of Asp601 was not favoured in the long term.
Cell-cell fusion and viral replication were also restored by a short
DN139INN deletion in V1 operating in conjunction with a D601N
pseudoreversion. In this case Env fusogenicity was maintained
despite a more labile gp120-gp41 complex. The DN139INN/
K601N phenotype was largely recapitulated by S144N/K601N,
suggesting that loss of the Asn142 glycan is sufficient to restore
fusion function when Asn601 is present in the DSR. Mutations
designed to ablate the remaining PNGSs at positions 141, 156, 160
and 186 within V1V2, did not restore function to Asn601-
containing Envs, indicating a specific functional linkage between
the DSR and the Asn136 and Asn142 glycans in the context of AD8
Env. It should be noted that V1V2 exhibits high degree of
diversity in sequence, length and numbers of PNGSs
[34,35,36,37,38,39,40,41,42,43,44]. It is therefore likely that the
functional linkages between particular V1V2 glycans and residues
within the gp120-gp41 association site will vary in a strain-
dependent manner.
The impacts of the V1 glycan changes on the gp120-gp41
association site were probed further by combining T138N, L494I
and DN139INN with various DSR mutations: L593V and K601D,
which disrupt gp120-gp41 association and fusion function, and
W596L which inhibits fusion [27,28]. The reverting mutations
were found to change the dependence of fusion and association on
these DSR residues. For example, T138N/L494I rendered
subunit association and fusion function largely independent of
Leu593 and Lys601, whereas less dependence on Lys601 was
observed with DN139INN. In the case of W596L, T138N and
DN139INN were sufficient to confer WT fusion levels, but this did
not involve changes to the WT-like gp120-gp41 association
phenotype of W596L. The fusion gains conferred to W596L
may involve transduction of a receptor-induced activation signal
from gp120 to gp41 through the association site in manner that is
Figure 6. Effects of T138N, DN139INN and L494I mutations on
gp120-gp41 association and cell-cell fusion activities of DSR
mutants. A, gp120-gp41 association. Lysates of metabolically labelled
Env-expressing cells (c) and corresponding culture supernatants (s)
were immunoprecipitated with IgG14 plus protein G-Sepharose and
subjected to SDS-PAGE and phosphorimager scanning. The panel was
prepared from 3 gels obtained from a single experiment using Adobe
Photoshop. gp120-shedding indices (mean6 standard error) are shown
below the corresponding immunoprecipitations and were calculated as
for Fig. 3C from at least 3 independent experiments. B, Cell-cell fusion.
Assays were conducted with 0.25 mg Env expression plasmids as for
FIG. 1F. Mean RLU 6 standard error (n$3) is shown. *, P,0.05;
** P,0.01; **, P,0.001; 2-tailed unpaired t test assuming unequal
variances.
doi:10.1371/journal.ppat.1003218.g006
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less dependent on Trp596. The earlier finding that W596L blocks
sCD4-induced formation of the gp41 prehairpin intermediate
indicates that Trp596 can play a role in receptor-triggered gp41
activation [29]. The generation of functional Env complexes with
stable gp120-gp41 association following the combination of V1
glycan mutations with various L593V, W596L or K601D DSR
mutations, may be mediated by a shifting of the points of
intersubunit contact to conserved residues at alternative positions
within the synapse [e.g. Gln591, Gly597, Thr606 and Trp610
[27,28,76]], and/or other regions of gp41 that appear to interact
with gp120, including the fusion-peptide proximal segment [77],
HR1 [78,79], and HR2 [76].
V1V2 comprises a conserved 4-stranded b-sheet minidomain
that is stabilized by 2 interstrand disulfides (Cys126-Cys196 and
Cys131-Cys157). The highly variable segments and PNGSs are for
the most part contained within the connecting loops (Fig. 8A) [7].
A model of glycosylated AD8 V1V2 based on the CAP45 V1V2
structure [7] indicates that 6 N-linked glycans would encompass
this minidomain in a hydrophilic shell (Fig. 8A). The most obvious
changes due to T138N and DN139INN would be the loss of
hydrophilic glycan bulk (,1840 A˚3 per high-mannose glycan; see
[80]) and, for the latter, a shortening of the V1 loop (Fig. 8A). N-
linked glycans have been found to induce local order in the
backbone of protein loop regions by destabilizing the unfolded
state, the increased entropy of the flexible glycan side chain
compensating for the decreased entropy of the protein backbone
[81,82,83]. The loss of the Asn136 and Asn142 glycans may lead to
localized disorder and structural change and/or instability within
V1, which in turn affects other structural elements of the gp120-
gp41 complex. Cryoelectron tomography indicates that the Asn136
and Asn142 V1 glycans would be located at the apex of the trimeric
Env spike whereas the gp120-gp41 association synapse is
underneath the gp120 trimer [8,12]. An allosteric mechanism
whereby changes in V1 can affect the structure of the distal gp120-
gp41 association site is suggested by the architecture of gp120,
wherein 3 structurally plastic layers of the core domain are linked
to the N- and C-terminal gp41-associating segments via an
invariant 7-stranded b-sandwich [8] (Fig. 8B). Layer 2 connects
Figure 7. Sensitivity of T138N and DN139INN mutant pseudovirions to NAbs. U87.CD4.CCR5 cells were incubated with pseudovirus-IgG
mixtures for 2 days prior to lysis and assay for luciferase activity. Neutralizing activities were measured in triplicate and reported as the average
percent luciferase activity. The data are representative of 2–4 independent experiments. WT: blue squares, T138N: red triangles, DN139INN: green ‘‘X’’s.
doi:10.1371/journal.ppat.1003218.g007
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Figure 8. Structural models. A, Homology model of oligomannose-glycosylated AD8 V1V2 based on the crystal structure of CAP45 V1V2 [7]. The
V1V2 model, generated using the Modeller algorithm [113] within Discovery Studio 3.0, was glycosylated in silico with oligomannose side chains
using the glycosciences.de server (http://www.glycosciences.de/modeling/glyprot/php/main.php) [114,115]. The b2–b3 hairpin that forms the V1V2
base is colored green, V1 in yellow, V2 in orange. PNGSs (Asn residues shown in CPK) and oligomannose side chains are colored according to the
V1V2 subdomain to which they are attached. B, Model of oligomannose-glycosylated gp120 monomer. The model, prepared with the UCSF Chimera
package [117], is based on the crystal structures of the complex formed between HXBc2 gp120 with gp41-interactive region (gp120 residues 31–284,
334–501), sCD4 and 48 d Fab (PDB ID 3JWD) and the YU2 gp120 (residues 285–333)-418d Fab-sCD4 complex (PDB ID 2QAD) [5,8]. Oligomannose
addition was performed in silico as for A. The gp41 association site formed by the N- and C-terminal segments is colored green, the 7 stranded b-
sandwich in purple, layer 2 and the V1V2 b2–b3 hairpin base in green, layer 1 in pink, the outer domain in red. Asn residues representing PNGSs are
shown in CPK. Oligomannose glycans implicated in 2G12 recognition are colored crimson. The homology models were drawn using Pymol. C,
Alignment of V1V2 amino acid sequences. Selected V1V2 sequences were initially aligned using clustalx and then adjusted manually. PNGSs are
highlighted in green. Residue numbering is according to HXB2. sens: neutralization-sensitive; res: neutralization-resistant. a, Neutralization
susceptibility of Envs derived from subtype B HIV-1 reference strains as determined using macaque antisera raised to SF162 gp140 immunogen [36];
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the b2-b3 hairpin that forms the base of V1V2 via the b-sandwich
to the gp120 N- and C-terminal segments (Fig. 8A, B). Thus
changes in V1V2 structure and/or stability due to the loss of the
Asn136 or Asn142 glycans may cause a distortion or displacement of
layer 2, which is translated to the N- and C-terminal gp41-
interacting segments via the b-sandwich. Our data suggest that the
glycan changes in V1 observed here involve a structural
remodeling of the gp120-gp41 association interface such that
Env function is less dependent on particular gp120-contact
residues within the DSR with conserved residues at alternative
positions within the synapse being employed for intersubunit
contact [27,28].
The V1V2 minidomain has been shown to modulate the
accessibility and/or conformation of the CD4-binding site and V3
loop [38,84,85,86,87], the latter of which mediates chemokine
receptor binding. Our data indicate that the sCD4-binding
abilities of monomeric gp120 molecules bearing 2nd and 3rd site
mutations in various combinations were not significantly different
to the WT, suggesting that changes in CD4-binding ability per se
do not contribute to the mechanism of reversion. However,
DN139INN/K601N-mediated cell-cell fusion and virus infectivity
were more resistant to sCD4 inhibition suggesting that the
conformation of the DN139INN/K601N Env trimer is subtly
different to that of WT and T138N/L494I/K601N. sCD4 has
been shown to primarily inhibit HIV-1 infection by inducing a
transiently activated glycoprotein complex that rapidly undergoes
irreversible conformational changes linked to a loss of function
[88]. This sCD4-mediated inactivation correlates with a rapid
decay in exposure of the HR1 coiled coil groove of the fusion-
activated gp41 prehairpin intermediate. It may be that the
apparently looser association between gp120 and gp41 of
DN139INN/K601N alters the conformational pathway of the
sCD4-induced state to enable maintenance of fusion competence.
A striking feature of gp120-gp41 is the occlusion of the
conserved protein surface by a glycan shield comprising ,24 N-
linked glycans on gp120 and 4–5 on gp41 [3,56,89,90,91]. An
evolving glycan shield is an important mediator of viral escape
from NAbs where an increase in the number and/or a change in
the position of PNGSs alter NAb sensitivity [35]. A number of
studies have indicated that V1V2 plays a particularly important
role in regulating neutralization resistance [36,38,41,42], which
generally correlates with V1V2 elongation and insertion of
PNGSs, in some cases at and C-terminal to position 136
(Fig. 8C) [34,37,38,39,40,42,43,44]. Our studies indicate that
subtle changes to the glycan shield in V1 impact on neutralization
by glycan-dependent brNAbs. For example, the Asn136 and Asn142
glycan mutations were found to increase the sensitivity of HIV-1
pseudovirions to the 2G12 NAb, which is dependent on high-
mannose glycans on the outer face of gp120, including those
attached to Asn295 and Asn332 at the base of V3, as well as Asn339,
Asn386 and Asn392 [63,64,65,66,67,68] (Fig. 8B). Neutralization
epitopes within V3 appear particularly sensitive to changes in
V1V2, which is likely due to the proximity between these variable
structures in the context of trimeric gp120-gp41 [10,12,38,84,86].
The Asn136 and Asn142 V1 glycan deletions may modulate the
structure and/or accessibility the 2G12 glycan epitope by altering
V1V2-V3 interactions in the context of trimeric gp120. Alterna-
tively, the enhanced neutralization of T138N and DN139INN by
2G12 may be a result of changes in the global antigenic structure
of gp120-gp41, as was suggested by the finding that the V1 glycan
deletions slightly enhanced the neutralization potency of poly-
clonal HIVIG. That V1V2 can regulate global antigenic structure
via changes in the glycan shield has been suggested by the finding
that glycosylation changes within gp120 at 197, 234, 295 and 301
contribute to the restoration of infectivity to viruses from which the
entire V1V2 region had been deleted [92]. We also observed that
DN139INN led to increased sensitivity to neutralization by NAb
PG16, whose complex epitope includes the V1V2 glycans at
Asn156 and Asn160 and is influenced by residues in V3 [7,69,70].
The AD8 V1V2 model suggests that the Asn142 glycan is proximal
to the Asn156 glycan, implying that the N139INN deletion may
relieve a steric constraint that enables better epitope access for
PG16. Alternatively, or additionally, changes in the disposition of
V3, as was implied by the increased sensitivity of DN139INN to
neutralization by 2G12, may contribute to the increased
neutralization efficacy of PG16. Overall, our data indicate that
the Asn136 and Asn142 glycans of V1 can modulate local (PG16)
and remote (2G12) glycan-dependent neutralization epitopes as
well as the global antigenic structure of Env (HIVIG) and that
these changes are functionally linked to a remodelling of the
gp120-gp41 association site. Our data also imply that glycan shield
evolution may indirectly affect the inhibitory potential of novel
fusion blockers, such as PF-68742, for which the DSR is a
component of their targeting mechanism [33]. Conversely, DSR
sequence evolution driven by potential DSR-directed entry
inhibitors may be associated with compensatory V1 glycan
changes as described here and the coevolution of neutralization
sensitivity.
Our previous work indicated that the gp120-gp41 association
interface is structurally and functionally plastic despite exhibiting a
high degree of sequence conservation [28]. In this study, we have
found that changes at the 136 and 142 V1 glycans that are
associated with neutralization sensitivity appear to remodel the
gp120-gp41 association site, rendering certain highly conserved
gp120-contact residues (i.e. Leu593, Trp596 and Lys601) less
important for gp120 association and fusion function, and thereby
implying that gp120-gp41 contact residues at alternative positions
within the synapse become utilized for these functions. The
allosteric modulation of the conserved DSR-C1–C5 synapse by
distal V1 glycans may represent a mechanism whereby functionally
relevant gp120-gp41 association is maintained as the virus acquires
neutralization resistance due to the evolution of its glycan shield.
Materials and Methods
Env expression vectors and proviral clones
The preparation of the cytomegalovirus promoter-driven HIV-
1AD8 Env expression vector, pCDNA3.1-AD8env, is described
elsewhere [28]. pDKAD8env was derived by religation of the end-
filled HindIII and EcoRI sites of pCDNA3.1-AD8env. In vitro
mutagenesis of the gp41 region was carried out by overlap
extension PCR. Mutants of the pAD8 infectious clone (obtained
from K. Peden [93] were prepared by transferring the EcoRI-
BspMI env-containing fragment from pCDNA3.1-AD8env vectors
into pAD8. Bacteriophage T7 promoter-driven gp120 expression
vectors, based on pTM.1 [94], were generated by ligating PCR-
amplified HIV-1AD8 gp120 fragments into the NdeI and StuI sites
of pTMenv.2 [95] to give pTM-AD8gp120.
b, Neutralization susceptibility phenotype associated with primary (M1) and chronic (M47, M46, M32 and M31) phase subtype A V1V2 sequences as
determined with autologous plasma [42]; c, Consensus V1V2 sequences derived from neutralization-sensitive (VP-1CON) and neutralization-resistant
(VP-2CON) isolates obtained from a patient with cross-reactive neutralizing activity as determined with autologous plasma [44].
doi:10.1371/journal.ppat.1003218.g008
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Infection of PBMCs
PBMC infections were conducted as described previously
[96]. Briefly, PBMCs isolated from buffy packs (Red Cross
Blood Bank, Melbourne) were stimulated with phytohemagglu-
tinin (10 mg/ml; Murex Diagnostics) for 3 days in RPMI 1640
medium containing 10% fetal calf serum and interleukin-2 (10
units/ml; Boehringer-Mannheim). Virus stocks were prepared
by transfecting 293T cell monolayers with pAD8 infectious
clones using Fugene 6 (Roche). Virus-containing transfection
supernatants were normalized according to reverse transcriptase
(RT) activity, and then used to infect 105 PBMCs in a 96-well
tissue culture plate (eight 10-fold serial dilutions of each virus
were tested in triplicate). The supernatants were assayed for RT
activity at various time points.
Sequential passage of cell-free K601D virus in PBMC
Phytohemagglutinin-stimulated PBMCs were infected with
equivalent amounts of wild type (WT) and K601D-mutated
HIV-1AD8 (according to RT activity) in parallel and maintained in
culture for 10 days. Cell-free culture supernatants were filtered
(0.45 mm pore size) and normalized according to RT activity prior
to the next passage (5 passages in total). Genomic DNA was
extracted from infected PBMCs using Qiagen DNeasy. The viral
DNA fragment encompassed by nucleotides 5954–9096 (HXB2R
numbering convention) was PCR-amplified using Expand HiFi
(Roche) and the primers, 59-GGCTTAGGCATCTCCTATGG-
CAGGAAGAA (Env1A) and 59-TAGCCCTTC-
CAGTCCCCCCTTTTCTTTTA (Env1M) [97]. The amplified
sequences were ligated into pGEM-T or pDKAD8env (KpnI-XbaI)
and the entire env open reading frame sequenced using ABI
BigDye terminator 3.1.
Western blotting
Lysates of Env-expressing 293T cells or virions pelleted from
pAD8-transfected 293T cell supernatants were subjected to SDS-
PAGE under reducing conditions, transferred to nitrocellulose and
then probed with mAb C8 to gp41 (from G. Lewis [98], DV-012
to gp120 (from M. Phelan [99,100], or mAb 183 to CA (from B.
Chesebro and K. Wehrly [101,102] (AIDS Research and
Reference Reagent Program, NIAID) as described [28].
Luciferase reporter assay of cell-cell fusion
Cell-cell fusion assays were conducted as described [77]. Briefly,
293T effector cells were cotransfected with pCDNA3.1-AD8env or
pDKAD8env and pCAG-T7 [103] plasmids, while BHK21 target
cells were cotransfected with pT4luc [27] and pc.CCR5 (AIDS
Research and Reference Reagent Program from N. Landau [104]
or a panel of CCR5 mutants in the pcDNA3 expression vector
(kind gifts of J. S. Sodroski and R. W. Doms [105,106]). The Y14N
mutation was introduced to pc.CCR5 using the Quikchange II XL
kit (Stratagene). At 24 h posttransfection, targets and effectors
were cocultured in triplicate in a 96-well plate (18 h, 37uC) and
then assayed for luciferase activity (Promega SteadyGlo, Madison,
Wis.). The sensitivities of WT and mutant Env proteins to the
fusion inhibitor peptide C34 (WMEWDREINNYTSLIH-
SLIEESQNQQEKNEQELL; Mimotopes, Australia [62]) were
determined by coculturing effector and target cells in the presence
of serially diluted C34. The sensitivities of WT and mutant Env
proteins to sCD4 (NIH AIDS Research and Reference Reagent
Program) were determined by incubating the Env-expressing
293T cells with a dilution series of sCD4 for 3.5 h followed by
coculturing the effector and target cells in the presence of sCD4 for
8 h.
Single cycle infectivity assays
Single cycle infectivity assays were conducted as described [77].
Briefly, Env-pseudotyped luciferase reporter viruses were pro-
duced by cotransfecting 293T cells with pCDNA3.1-AD8env or
pDKAD8env vectors plus the luciferase reporter virus vector,
pNL4.3.Luc.R2E2 (AIDS Research and Reference Reagent
Program, N. Landau [107]), using Fugene 6. The infectivity of
pseudotyped viruses was determined in U87.CD4.CCR5 cells
(AIDS Research and Reference Reagent Program, H. Deng and
D. Littman [108]).
Biosynthetic labelling and immunoprecipitation
293T cells were transfected with pCDNA3.1-AD8env or
pDKAD8env vectors. At 24-h posttransfection, the cells were
incubated for 30 min in cysteine and methionine-deficient
medium (MP Biomedicals, Seven Hills, NSW, Australia), and
then labelled for 45 min with 150 mCi Tran-35S-label (MP
Biomedicals). The cells were then washed and chased in complete
medium for 5–6 h prior to lysis. Cell lysates and clarified culture
supernatants were immunoprecipitated with IgG14 or HIVIG and
protein G Sepharose and subjected to SDS-PAGE in the presence
of ß-mercaptoethanol [28]. The labelled proteins were visualized
by scanning in a Fuji phosphorimager. Quantitation of bands was
performed using Image Gauge (FUJIFILM) software.
Kifunensine treatment of transfected cells
To determine the effects of the competitive a-mannosidase
inhibitor, kifunensine (Sigma), on Env synthesis and processing,
cell-cell fusion and gp120-gp41 association, the compound was
added to 293T cells at the time of transfection, and was
maintained at the concentrations indicated in the results section
through each step of the assays described above.
gp120-sCD4 binding assay
293T cells were cotransfected with pTM-AD8gp120 and pCAG-
T7 vectors using Fugene 6. At 24-h posttransfection, the cells were
incubated for 30 min in cysteine and methionine-deficient medium,
labelled for 45 min with 150 mCi Tran-35S-label, and then washed
and chased in complete medium for 6 h. The clarified culture
supernatants were adjusted to 0.6 M KCl, 1 mM EDTA and 1%
w/v Triton-X100 and the gp120 content quantified following
immunoprecipitation with IgG14 and protein G Sepharose,
reducing SDS-PAGE and scanning in a Fuji phosphorimager.
Equivalent amounts of WT and mutant gp120 proteins were
incubated with serial dilutions of sCD4 (1 h, room temperature) and
then incubated with mAb OKT4 and BSA-Sepharose on a
vibrating platform (30 min, room temperature). After pelleting the
BSA-Sepharose, protein complexes were coprecipitated using
protein G-Sepharose and gp120 quantified following reducing
SDS-PAGE and scanning in a Fuji phosphorimager.
Neutralization of infection by sCD4-IgG2
Wild type, T138N/L494I/K601N and DN139INN/K601N
virus stocks were adjusted such that ,26106 relative light units
(RLU) were obtained following a 48 h-infection of TZM-bl cells, a
HeLa cell line expressing CD4 and CCR5 and harbouring
integrated copies of the luciferase and b-galactosidase genes under
control of the HIV-1 promoter (obtained from J. C. Kappes, X.
Wu and Tranzyme Inc., NIH AIDS Research and Reference
Reagent Program [109,110,111]). A dilution series of CD4-IgG2,
a tetrameric fusion protein comprising human IgG in which the Fv
domains have been replaced by domains 1 and 2 of human CD4
(Progenics Pharamceuticals, NIH AIDS Research and Reference
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Reagent Program), was incubated with the viruses for 4 h at 37uC
prior to addition to TZM-bl cells (200 ml; 104 cells in 96-well
culture plates). The cells were lysed 48 later and assayed for
luciferase activity (Promega).
Neutralization assay
Neutralization assays were conducted using a modification of
the method of Dhillon et al. [112]. Briefly, a solution of Env-
pseudotyped luciferase reporter viruses determined previously to
give ,56105 RLU following infection of U87.CD4.CCR5 cells
was mixed with an equal volume of serially diluted IgG and
incubated for 1 h at 37uC. One hundred microliters of the virus-
IgG mixtures was then added to U87.CD4.CCR5 cells (104 cells
per well of a 96-well tissue culture plate, 100 microlitres) and
incubated for 2 days prior to lysis and assay for luciferase activity
(Promega, Madison, WI). Neutralizing activities for antibody
samples were measured in triplicate and reported as the average
percent luciferase activity. Purified IgG of monoclonal NAbs 2F5,
2G12 and IgGb12 were obtained from Polymun Scientific
(Austria), PG16 was obtained from the International AIDS
Vaccine Initiative, while HIVIG was obtained from F. Prince
through the NIAID AIDS Research and Reference Reagent
Program.
Molecular modeling
A homology-based model of HIV-1AD8 V1V2 was generated
from PDB entry 3U4E [7] using the Modeller algorithm [113]
within Discovery Studio, version 3.0 (Accelrys). Five independent
models were generated from iterative cycles of conjugate-gradient
energy minimization against spatial constraints derived from the
template crystal structure. The model with the lowest energy
(probability density function) was glycosylated in silico with
oligomannose side chains using the glycosciences.de server
(http://www.glycosciences.de/modeling/glyprot/php/main.php)
[114,115].
Supporting Information
Figure S1 Effect of kifunensine on Env synthesis and function.
A, Western blot. Kifunensine was added to 293T cells at the time
of transfection with DKADenv expression vectors. The transfected
cells were cultured in the presence and absence of kifunensine for a
further 48 h prior to lysis, reducing SDS-PAGE and Western
blotting with DV-012 to gp120 (top panel) or 2F5 to gp41 (bottom
panel). B, Cell-cell fusion. 293T cells were cotransfected with
DKADenv expression vectors plus pCAG-T7 and cultured in the
presence or absence of 10 mM kifunensine. At 24 h posttransfec-
tion, the cells were detached and cocultured for a further 18 h with
pT4luc plus pcCCR5-cotransfected BHK-21 cells in the presence
or absence of 10 mM kifunensine prior to lysis and assay for
luciferase activity. ** P,0.01; **, P,0.001; T138N/L494I/
K601N and DNINN/K601N versus K601D at the same kifunen-
sine concentration; 2-tailed unpaired t test assuming unequal
variances (n = 5). C, gp120-gp41 association. Kifunensine was
added to 293T cells at the time of transfection with DKADenv
expression vectors. At 24 h posttransfection, the cells were pulse-
chase metabolically labelled in the presence or absence of 10 mM
kifunensine prior to immunoprecipitation of culture supernatants
(s) and cell lysates (c) with HIVIG, reducing SDS-PAGE and
phosphorimager scanning.
(TIF)
Table S1 Summary of cell-cell fusion, gp120-gp41 association
and replication characteristics of revertant Env clones.
(DOCX)
Author Contributions
Performed the molecular modelling: PAR PP. Conceived and designed the
experiments: HED PP. Performed the experiments: HED MKH ALM SW
JM PP. Analyzed the data: HED MKH ALM SW PAR JM PP.
Contributed reagents/materials/analysis tools: HED MKH ALM SW
PAR JM PP. Wrote the paper: PP HED.
References
1. Checkley MA, Luttge BG, Freed EO (2011) HIV-1 envelope glycoprotein
biosynthesis, trafficking, and incorporation. J Mol Biol 410: 582–608.
2. Melikyan GB (2011) Membrane fusion mediated by human immunodeficiency
virus envelope glycoprotein. Curr Top Membr 68: 81–106.
3. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, et al. (2005) Structure of an
unliganded simian immunodeficiency virus gp120 core. Nature 433: 834–841.
4. Huang CC, Stricher F, Martin L, Decker JM, Majeed S, et al. (2005) Scorpion-
toxin mimics of CD4 in complex with human immunodeficiency virus gp120
crystal structures, molecular mimicry, and neutralization breadth. Structure 13:
755–768.
5. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, et al. (2007) Structures
of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120
and CD4. Science 317: 1930–1934.
6. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998)
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4
receptor and a neutralizing human antibody. Nature 393: 648–659.
7. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011)
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody
PG9. Nature 480: 336–343.
8. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, et al. (2010) Structure of
HIV-1 gp120 with gp41-interactive region reveals layered envelope architec-
ture and basis of conformational mobility. Proc Natl Acad Sci U S A 107:
1166–1171.
9. Basmaciogullari S, Babcock GJ, Van Ryk D, Wojtowicz W, Sodroski J (2002)
Identification of conserved and variable structures in the human immunode-
ficiency virus gp120 glycoprotein of importance for CXCR4 binding. J Virol
76: 10791–10800.
10. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S (2008) Molecular
architecture of native HIV-1 gp120 trimers. Nature 455: 109–113.
11. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, et al. (1998)
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor
binding. Science 280: 1949–1953.
12. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, et al.
(2010) Molecular architectures of trimeric SIV and HIV-1 envelope
glycoproteins on intact viruses: strain-dependent variation in quaternary
structure. PLoS Pathog 6: e1001249.
13. Colman PM, Lawrence MC (2003) The structural biology of type I viral
membrane fusion. Nat Rev Mol Cell Biol 4: 309–319.
14. Eckert DM, Kim PS (2001) Mechanisms of viral membrane fusion and its
inhibition. Annu Rev Biochem 70: 777–810.
15. Chang DK, Cheng SF, Trivedi VD (1999) Biophysical characterization of the
structure of the amino-terminal region of gp41 of HIV-1. Implications on viral
fusion mechanism. J Biol Chem 274: 5299–5309.
16. Furuta RA, Wild CT, Weng Y, Weiss CD (1998) Capture of an early fusion-
active conformation of HIV-1 gp41. Nature Struct Biol 5: 276–279.
17. He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, et al. (2003) Peptides trap the
human immunodeficiency virus type 1 envelope glycoprotein fusion interme-
diate at two sites. J Virol 77: 1666–1671.
18. Sackett K, Shai Y (2005) The HIV fusion peptide adopts intermolecular
parallel beta-sheet structure in membranes when stabilized by the adjacent N-
terminal heptad repeat: a 13C FTIR study. J Mol Biol 350: 790–805.
19. Lai AL, Moorthy AE, Li Y, Tamm LK (2012) Fusion activity of HIV gp41
fusion domain is related to its secondary structure and depth of membrane
insertion in a cholesterol-dependent fashion. J Mol Biol 418: 3–15.
20. Caffrey M, Cai M, Kaufman J, Stahl SJ, Wingfield PT, et al. (1998) Three-
dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J
17: 4572–4584.
21. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the
HIV envelope glycoprotein. Cell 89: 263–273.
22. Tan K, Liu J, Wang J, Shen S, Lu M (1997) Atomic structure of a thermostable
subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 94: 12303–12308.
23. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic
structure of the ectodomain from HIV-1 gp41. Nature 387: 426–430.
24. Yang ZN, Mueser TC, Kaufman J, Stahl SJ, Wingfield PT, et al. (1999) The
crystal structure of the SIV gp41 ectodomain at 1.47 A resolution. J Struct Biol
126: 131–144.
25. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, et al. (2000) A
recombinant human immunodeficiency virus type 1 envelope glycoprotein
V1 Glycans Modulate HIV-1 gp120-gp41 Association
PLOS Pathogens | www.plospathogens.org 16 April 2013 | Volume 9 | Issue 4 | e1003218
complex stabilized by an intermolecular disulfide bond between the gp120 and
gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
J Virol 74: 627–643.
26. Helseth E, Olshevsky U, Furman C, Sodroski J (1991) Human immunodefi-
ciency virus type 1 gp120 envelope glycoprotein regions important for
association with the gp41 transmembrane glycoprotein. J Virol 65: 2119–2123.
27. Maerz AL, Drummer HE, Wilson KA, Poumbourios P (2001) Functional
analysis of the disulfide-bonded loop/chain reversal region of human
immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41
association. J Virol 75: 6635–6644.
28. Poumbourios P, Maerz AL, Drummer HE (2003) Functional evolution of the
HIV-1 envelope glycoprotein 120 association site of glycoprotein 41. J Biol
Chem 278: 42149–42160.
29. Bellamy-McIntyre AK, Bar S, Ludlow L, Drummer HE, Poumbourios P (2010)
Role for the disulfide-bonded region of human immunodeficiency virus type 1
gp41 in receptor-triggered activation of membrane fusion function. Biochem
Biophys Res Commun 394: 904–908.
30. Abrahamyan LG, Markosyan RM, Moore JP, Cohen FS, Melikyan GB (2003)
Human immunodeficiency virus type 1 env with an intersubunit disulfide bond
engages coreceptors but requires bond reduction after engagement to induce
fusion. J Virol 77: 5829–5836.
31. Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, et al. (2003) Redox-
triggered infection by disulfide-shackled human immunodeficiency virus type 1
pseudovirions. J Virol 77: 5678–5684.
32. Finzi A, Xiang SH, Pacheco B, Wang L, Haight J, et al. (2010) Topological
layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-
triggered conformational transitions. Mol Cell 37: 656–667.
33. Murray EJ, Leaman DP, Pawa N, Perkins H, Pickford C, et al. (2010) A low-
molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of
human immunodeficiency virus type 1 targets a novel site on gp41. J Virol 84:
7288–7299.
34. Reitter JN, Means RE, Desrosiers RC (1998) A role for carbohydrates in
immune evasion in AIDS. Nat Med 4: 679–684.
35. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody
neutralization and escape by HIV-1. Nature 422: 307–312.
36. Ching LK, Vlachogiannis G, Bosch KA, Stamatatos L (2008) The first
hypervariable region of the gp120 Env glycoprotein defines the neutralizing
susceptibility of heterologous human immunodeficiency virus type 1 isolates to
neutralizing antibodies elicited by the SF162gp140 immunogen. J Virol 82:
949–956.
37. Kolchinsky P, Kiprilov E, Sodroski J (2001) Increased neutralization sensitivity
of CD4-independent human immunodeficiency virus variants. J Virol 75:
2041–2050.
38. Krachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, et al.
(2006) Factors determining the breadth and potency of neutralization by V3-
specific human monoclonal antibodies derived from subjects infected with clade
A or clade B strains of human immunodeficiency virus type 1. J Virol 80: 7127–
7135.
39. Losman B, Bolmstedt A, Schonning K, Bjorndal A, Westin C, et al. (2001)
Protection of neutralization epitopes in the V3 loop of oligomeric human
immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides
in the V1 region. AIDS Res Hum Retroviruses 17: 1067–1076.
40. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, et al. (2008) Removal of a
single N-linked glycan in human immunodeficiency virus type 1 gp120 results
in an enhanced ability to induce neutralizing antibody responses. J Virol 82:
638–651.
41. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, et al. (2004) The
V1/V2 domain of gp120 is a global regulator of the sensitivity of primary
human immunodeficiency virus type 1 isolates to neutralization by antibodies
commonly induced upon infection. J Virol 78: 5205–5215.
42. Sagar M, Wu X, Lee S, Overbaugh J (2006) Human immunodeficiency virus
type 1 V1–V2 envelope loop sequences expand and add glycosylation sites over
the course of infection, and these modifications affect antibody neutralization
sensitivity. J Virol 80: 9586–9598.
43. van Gils MJ, Bunnik EM, Boeser-Nunnink BD, Burger JA, Terlouw-Klein M,
et al. (2011) Longer V1V2 region with increased number of potential N-linked
glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-
specific neutralizing antibodies. J Virol 85: 6986–6995.
44. van Gils MJ, Edo-Matas D, Bowles EJ, Burger JA, Stewart-Jones GB, et al.
(2011) Evolution of human immunodeficiency virus type 1 in a patient with
cross-reactive neutralizing activity in serum. J Virol 85: 8443–8448.
45. Day JR, Van Damme N, Guatelli JC (2006) The effect of the membrane-
proximal tyrosine-based sorting signal of HIV-1 gp41 on viral infectivity
depends on sequences within gp120. Virology 354: 316–327.
46. Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, et al. (2007) A
comparative immunogenicity study of HIV-1 virus-like particles bearing
various forms of envelope proteins, particles bearing no envelope and soluble
monomeric gp120. Virology 366: 245–262.
47. Crooks ET, Tong T, Osawa K, Binley JM (2011) Enzyme digests eliminate
nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers
intact and viral infectivity unaffected. J Virol 85: 5825–5839.
48. Karlsson GB, Gao F, Robinson J, Hahn B, Sodroski J (1996) Increased
envelope spike density and stability are not required for the neutralization
resistance of primary human immunodeficiency viruses. J Virol 70: 6136–6142.
49. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, et al. (2006) Nature of
nonfunctional envelope proteins on the surface of human immunodeficiency
virus type 1. J Virol 80: 2515–2528.
50. Tong T, Crooks ET, Osawa K, Binley JM (2012) HIV-1 virus-like particles
bearing pure env trimers expose neutralizing epitopes but occlude nonneu-
tralizing epitopes. J Virol 86: 3574–3587.
51. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, et al. (1999)
Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell
96: 667–676.
52. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW (1999)
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets,
dendritic cells, and differentially conditioned monocyte-derived macrophages.
Proc Natl Acad Sci U S A 96: 5215–5220.
53. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, et al. (1999) Epitope
mapping of CCR5 reveals multiple conformational states and distinct but
overlapping structures involved in chemokine and coreceptor function. J Biol
Chem 274: 9617–9626.
54. Zaitseva M, Peden K, Golding H (2003) HIV coreceptors: role of structure,
posttranslational modifications, and internalization in viral-cell fusion and as
targets for entry inhibitors. Biochim Biophys Acta 1614: 51–61.
55. Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, et al. (2011) The
glycan shield of HIV is predominantly oligomannose independently of
production system or viral clade. PLoS One 6: e23521.
56. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, et al. (2010)
Envelope glycans of immunodeficiency virions are almost entirely oligoman-
nose antigens. Proc Natl Acad Sci U S A 107: 13800–13805.
57. Vallee F, Karaveg K, Herscovics A, Moremen KW, Howell PL (2000)
Structural basis for catalysis and inhibition of N-glycan processing class I alpha
1,2-mannosidases. J Biol Chem 275: 41287–41298.
58. Scanlan CN, Ritchie GE, Baruah K, Crispin M, Harvey DJ, et al. (2007)
Inhibition of mammalian glycan biosynthesis produces non-self antigens for a
broadly neutralising, HIV-1 specific antibody. J Mol Biol 372: 16–22.
59. Brighty DW, Rosenberg M, Chen IS, Ivey-Hoyle M (1991) Envelope proteins
from clinical isolates of human immunodeficiency virus type 1 that are
refractory to neutralization by soluble CD4 possess high affinity for the CD4
receptor. Proc Natl Acad Sci U S A 88: 7802–7805.
60. Litwin V, Nagashima KA, Ryder AM, Chang CH, Carver JM, et al. (1996)
Human immunodeficiency virus type 1 membrane fusion mediated by a
laboratory-adapted strain and a primary isolate analyzed by resonance energy
transfer. J Virol 70: 6437–6441.
61. Kuhmann SE, Platt EJ, Kozak SL, Kabat D (2000) Cooperation of multiple
CCR5 coreceptors is required for infections by human immunodeficiency virus
type 1. J Virol 74: 7005–7015.
62. Chan DC, Chutkowski CT, Kim PS (1998) Evidence that a prominent cavity in
the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad
Sci U S A 95: 15613–15617.
63. Chen H, Xu X, Bishop A, Jones IM (2005) Reintroduction of the 2G12 epitope
in an HIV-1 clade C gp120. AIDS 19: 833–835.
64. Duenas-Decamp MJ, Clapham PR (2010) HIV-1 gp120 determinants proximal
to the CD4 binding site shift protective glycans that are targeted by monoclonal
antibody 2G12. J Virol 84: 9608–9612.
65. Gray ES, Moore PL, Pantophlet RA, Morris L (2007) N-linked glycan
modifications in gp120 of human immunodeficiency virus type 1 subtype C
render partial sensitivity to 2G12 antibody neutralization. J Virol 81: 10769–
10776.
66. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, et al.
(2002) The mannose-dependent epitope for neutralizing antibody 2G12 on
human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76: 7293–
7305.
67. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et
al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1
antibody 2G12 recognizes a cluster of alpha1R2 mannose residues on the
outer face of gp120. J Virol 76: 7306–7321.
68. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996)
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope
on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70:
1100–1108.
69. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, et al. (2011) Potent
and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a
quaternary epitope including residues in the V2 loop. J Virol 85: 3128–3141.
70. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009)
Broad and potent neutralizing antibodies from an African donor reveal a new
HIV-1 vaccine target. Science 326: 285–289.
71. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, 3rd, et al. (1994)
Recognition properties of a panel of human recombinant Fab fragments to the
CD4 binding site of gp120 that show differing abilities to neutralize human
immunodeficiency virus type 1. J Virol 68: 4821–4828.
72. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural
definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:
732–737.
73. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved
neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol
67: 6642–6647.
V1 Glycans Modulate HIV-1 gp120-gp41 Association
PLOS Pathogens | www.plospathogens.org 17 April 2013 | Volume 9 | Issue 4 | e1003218
74. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, et al. (2004) Structure
and mechanistic analysis of the anti-human immunodeficiency virus type 1
antibody 2F5 in complex with its gp41 epitope. J Virol 78: 10724–10737.
75. Song L, Sun ZY, Coleman KE, Zwick MB, Gach JS, et al. (2009) Broadly
neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at
the membrane interface. Proc Natl Acad Sci U S A 106: 9057–9062.
76. York J, Nunberg JH (2004) Role of hydrophobic residues in the central
ectodomain of gp41 in maintaining the association between human
immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and
gp41. J Virol 78: 4921–4926.
77. Bellamy-McIntyre AK, Lay CS, Baar S, Maerz AL, Talbo GH, et al. (2007)
Functional links between the fusion peptide-proximal polar segment and
membrane-proximal region of human immunodeficiency virus gp41 in distinct
phases of membrane fusion. J Biol Chem 282: 23104–23116.
78. Leavitt M, Park EJ, Sidorov IA, Dimitrov DS, Quinnan GV, Jr. (2003)
Concordant modulation of neutralization resistance and high infectivity of the
primary human immunodeficiency virus type 1 MN strain and definition of a
potential gp41 binding site in gp120. J Virol 77: 560–570.
79. Park EJ, Quinnan GV, Jr. (1999) Both neutralization resistance and high
infectivity phenotypes are caused by mutations of interacting residues in the
human immunodeficiency virus type 1 gp41 leucine zipper and the gp120
receptor- and coreceptor-binding domains. J Virol 73: 5707–5713.
80. Meldal M, St Hilaire PM (1997) Synthetic methods of glycopeptide assembly,
and biological analysis of glycopeptide products. Curr Opin Chem Biol 1: 552–
563.
81. Imperiali B, O’Connor SE (1999) Effect of N-linked glycosylation on
glycopeptide and glycoprotein structure. Curr Opin Chem Biol 3: 643–649.
82. Shental-Bechor D, Levy Y (2008) Effect of glycosylation on protein folding: a
close look at thermodynamic stabilization. Proc Natl Acad Sci U S A 105:
8256–8261.
83. Shental-Bechor D, Levy Y (2009) Folding of glycoproteins: toward under-
standing the biophysics of the glycosylation code. Curr Opin Struct Biol 19:
524–533.
84. Liu L, Cimbro R, Lusso P, Berger EA (2011) Intraprotomer masking of third
variable loop (V3) epitopes by the first and second variable loops (V1V2) within
the native HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A 108:
20148–20153.
85. Musich T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, Robinson J, et
al. (2011) A conserved determinant in the V1 loop of HIV-1 modulates the V3
loop to prime low CD4 use and macrophage infection. J Virol 85: 2397–2405.
86. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, et al. (2011)
Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the
HIV envelope trimer against cross-neutralizing antibodies. J Exp Med 208:
1419–1433.
87. Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, et al. (2005)
The V1, V2, and V3 regions of the human immunodeficiency virus type 1
envelope differentially affect the viral phenotype in an isolate-dependent
manner. J Virol 79: 9069–9080.
88. Haim H, Si Z, Madani N, Wang L, Courter JR, et al. (2009) Soluble CD4 and
CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived
activated state. PLoS Pathog 5: e1000360.
89. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA (2000)
Oligomeric modeling and electrostatic analysis of the gp120 envelope
glycoprotein of human immunodeficiency virus. J Virol 74: 1961–1972.
90. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, et al. (1990)
Assignment of intrachain disulfide bonds and characterization of potential
glycosylation sites of the type 1 recombinant human immunodeficiency virus
envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol
Chem 265: 10373–10382.
91. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The
antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705–
711.
92. Bontjer I, Land A, Eggink D, Verkade E, Tuin K, et al. (2009) Optimization of
human immunodeficiency virus type 1 envelope glycoproteins with V1/V2
deleted, using virus evolution. J Virol 83: 368–383.
93. Theodore TS, Englund G, Buckler-White A, Buckler CE, Martin MA, et al.
(1996) Construction and characterization of a stable full-length macrophage-
tropic HIV type 1 molecular clone that directs the production of high titers of
progeny virions. AIDS Res Hum Retroviruses 12: 191–194.
94. Moss B, Elroy-Stein O, Mizukami T, Alexander WA, Fuerst TR (1990) New
mammalian expression vectors. Nature 348: 91–92.
95. Poumbourios P, Wilson KA, Center RJ, El Ahmar W, Kemp BE(1997) Human
immunodeficiency virus type 1 envelope glycoprotein oligomerization requires
the gp41 amphipathic alpha-helical/leucine zipper-like sequence. J Virol 71:
2041–2049.
96. Hill MK, Shehu-Xhilaga M, Campbell SM, Poumbourios P, Crowe SM, et al.
(2003) The dimer initiation sequence stem-loop of human immunodeficiency
virus type 1 is dispensable for viral replication in peripheral blood mononuclear
cells. J Virol 77: 8329–8335.
97. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, et al. (1996)
Molecular cloning and analysis of functional envelope genes from human
immunodeficiency virus type 1 sequence subtypes A through G. The WHO
and NIAID Networks for HIV Isolation and Characterization. J Virol 70:
1651–1667.
98. Abacioglu YH, Fouts TR, Laman JD, Claassen E, Pincus SH, et al. (1994)
Epitope mapping and topology of baculovirus-expressed HIV-1 gp160
determined with a panel of murine monoclonal antibodies. AIDS Res Hum
Retroviruses 10: 371–381.
99. Hatch WC, Tanaka KE, Calvelli T, Rashbaum WK, Kress Y, et al. (1992)
Persistent productive HIV-1 infection of a CD4- human fetal thymocyte line.
J Immunol 148: 3055–3061.
100. Page KA, Stearns SM, Littman DR (1992) Analysis of mutations in the V3
domain of gp160 that affect fusion and infectivity. J Virol 66: 524–533.
101. Chesebro B, Wehrly K, Nishio J, Perryman S (1992) Macrophage-tropic
human immunodeficiency virus isolates from different patients exhibit unusual
V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates:
definition of critical amino acids involved in cell tropism. J Virol 66: 6547–
6554.
102. Toohey K, Wehrly K, Nishio J, Perryman S, Chesebro B (1995) Human
immunodeficiency virus envelope V1 and V2 regions influence replication
efficiency in macrophages by affecting virus spread. Virology 213: 70–79.
103. Takikawa S, Ishii K, Aizaki H, Suzuki T, Asakura H, et al. (2000) Cell fusion
activity of hepatitis C virus envelope proteins. J Virol 74: 5066–5074.
104. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, et al. (1996) Identification of
a major co-receptor for primary isolates of HIV-1. Nature 381: 661–666.
105. Doranz BJ, Lu ZH, Rucker J, Zhang TY, Sharron M, et al. (1997) Two distinct
CCR5 domains can mediate coreceptor usage by human immunodeficiency
virus type 1. J Virol 71: 6305–6314.
106. Farzan M, Choe H, Vaca L, Martin K, Sun Y, et al. (1998) A tyrosine-rich
region in the N terminus of CCR5 is important for human immunodeficiency
virus type 1 entry and mediates an association between gp120 and CCR5.
J Virol 72: 1160–1164.
107. Connor RI, Chen BK, Choe S, Landau NR (1995) Vpr is required for efficient
replication of human immunodeficiency virus type-1 in mononuclear
phagocytes. Virology 206: 935–944.
108. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, et al. (1997)
Coreceptor usage of primary human immunodeficiency virus type 1 isolates
varies according to biological phenotype. J Virol 71: 7478–7487.
109. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O’Brien WA, et al. (2000)
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-
20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
J Virol 74: 8358–8367.
110. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC (2009) Evidence that
ecotropic murine leukemia virus contamination in TZM-bl cells does not affect
the outcome of neutralizing antibody assays with human immunodeficiency
virus type 1. J Virol 83: 8289–8292.
111. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of
resistant human immunodeficiency virus type 1 in patients receiving fusion
inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896–1905.
112. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, et al. (2007)
Dissecting the neutralizing antibody specificities of broadly neutralizing sera
from human immunodeficiency virus type 1-infected donors. J Virol 81: 6548–
6562.
113. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of
spatial restraints. J Mol Biol 234: 779–815.
114. Bohne-Lang A, von der Lieth CW (2005) GlyProt: in silico glycosylation of
proteins. Nucleic Acids Res 33: W214–219.
115. Lutteke T, Bohne-Lang A, Loss A, Goetz T, Frank M, et al. (2006)
GLYCOSCIENCES.de: an Internet portal to support glycomics and
glycobiology research. Glycobiology 16: 71R–81R.
116. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, et al. (1986)
Production of acquired immunodeficiency syndrome-associated retrovirus in
human and nonhuman cells transfected with an infectious molecular clone.
J Virol 59: 284–291.
117. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al.
(2004) UCSF Chimera–a visualization system for exploratory research and
analysis. J Comput Chem 25: 1605–1612.
V1 Glycans Modulate HIV-1 gp120-gp41 Association
PLOS Pathogens | www.plospathogens.org 18 April 2013 | Volume 9 | Issue 4 | e1003218
